Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04757870
Other study ID # KCU_16022021
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date March 1, 2021
Est. completion date December 31, 2021

Study information

Verified date February 2021
Source Izmir Katip Celebi University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study, investigators try to estimate Covid-19 Cases and Deaths using countrywide annual macro-scale indicators (i.e., estimators) such as non-communicable disease data from WHO (who. int), social and economical indicators from UN (un.org) and Worldbank (worldbank.org), and Covid-19 Cases and Deaths from Worldometer (https://www.worldometers.info).


Description:

There are some known risk factors for the emergence and mortality of Covid-19 cases. There are also some regulations and recommendations by healthcare executives and government officers such as wearing masks, social distance, staying at home, lockdowns, and so forth. On the other hand, there could be other social, economic, and health-related factors in the society level that discriminate between countries significantly in terms of having considerable differences regarding both the frequency and mortality of Covid-19. The aim of the present study is to find out these social, economic, and health-related factors that could explain some significant portion of Covid-19 cases and deaths worldwide. This study involves 171 countries of which required datasets are commonly available in the UN, Worldometer, and WHO. The investigators will obtain macro-scale indicators like non-communicable disease data from WHO (who. int), social and economical indicators from UN (un.org) and Worldbank (worldbank.org), and Covid-19 data from Worldometer (https://www.worldometers.info). The investigators will conduct statistical data analysis and create predictive models in order to determine indicators. The investigators will also consider that possible different models for explaining Covid-19 Cases and mortality in both common and different estimators could explain the variations in countrywide deaths and cases.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 1790
Est. completion date December 31, 2021
Est. primary completion date June 30, 2021
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All recorded cases by the authority Exclusion Criteria: - None

Study Design


Related Conditions & MeSH terms


Intervention

Other:
frequency
Macro-scale risk factors for the frequency of and mortality of infection

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Dr. Servet Akar Dokuz Eylul University, Hacettepe University

Outcome

Type Measure Description Time frame Safety issue
Primary Occurence The frequency of infection according to publicly available data december 2020
Secondary Mortality The mortality of infection according to publicly available data december 2020
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3